Notice of Intent to Sole Source - M201 ProDrug_Approved for posting 16NOV26.pdf
PDF 126 KB Posted
- Solicitation number
- HT9426-27-NOI-049825
- Issued by
- Not on record
About this file
This is a Notice of Intent (NOI) to Sole Source a federal contract opportunity.
The Defense Health Agency Contracting Activity (DHACA), on behalf of the Walter Reed Army Institute of Research (WRAIR), Center for Military Psychiatry and Neuroscience (CMPN), Integrative Systems Biology (ISB) Branch, intends to negotiate on a sole source basis with Mitochon Pharmaceuticals, Inc. (970 Cross Lane, Blue Bell, PA 19422-1574) for the supply of two batches of the proprietary prodrug MP201 for testing Acute Stress Reactions (ASRs). The contractor shall deliver freshly synthesized lots of MP201 in dosage quantities ranging from approximately 8-80 mg/kg body weight, formulated for oral administration in mice. The contract also requires the contractor to provide quality control documentation, dosage background information, and informational support to the ISB research team for preparing reports and manuscripts related to MP201. The Product Service Code is AN14 (Health R&D Services; Health Care Services; R&D Administrative Expenses), the NAICS Code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences), and the small business size standard is 1,000 employees.
Responsible and interested parties may submit capability statements in PDF, MS Word, or Excel format by 2:00 p.m. Eastern Time on December 31, 2026, to Herbert Keen (herbert.e.keen.civ@health.mil) and Lance Nowell (lance.l.nowell.civ@health.mil). Submissions must include supporting evidence demonstrating the firm's ability to provide the stated capability. The Government reserves the right to determine whether a competitive procurement is in the best interest of the Government; however, if no responses are received, the DHACA will proceed with the sole source contract award to Mitochon Pharmaceuticals, Inc. Submitted materials will not be returned, and classified material must not be submitted.
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Notice of Intent (NOI) to Sole Source
Requireing Activity: Walter Reed Army Institute of Research (WRAIR), Center for Military
Psychiatry and Neuroscience (CMPN), Integrative Systems Biology (ISB) Branch
Notice ID – HT9426-27-NOI-049825
Related Notice: N/A
Product Service Code (PSC): AN14 - I HEALTH R&D SERVICES; HEALTH CARE SERVICES;
R&D ADMINISTRATIVE EXPENSES
North American Industry Classification System (NAICS) Code: 541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Small Business Size Standard: 1,000 employees
The Defense Health Agency Contracting Activity (DHACA) on behalf of the WRAIR, CMPN, ISB, intends to negotiate on a sole source basis in accordance with RFO 6.103 with vendor Mitochon
Pharmaceuticals, Inc. 970 Cross Lane, Blue Bell, PA 19422-1574.
The contractor shall supply two (2) Batches of the proprietary prodrug MP201 to ISB for testing Acute
Stress Reactions (ASRs). This includes providing quality control documentation and dosage background information. Additionally, the contractor shall provide informational support to the ISB research team by assisting with preparing reports and manuscripts related to MP201. Each batch of synthesized MP201 shall consist of a freshly made lot of prodrug to determine target dosage in the range of approximately 8 - 80 mg/kg body weight. These doses shall be developed in quantities to support oral administration in mice.
THIS NOI IS NOT A REQUEST FOR COMPETITIVE PROPOSALS, and no solicitation document exists for this requirement. Meaningful submissions received in response to this notice will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government..
Responsible, interested parties may identify their interest by submitting capability statements (using
PDF, MS Word, or Excel attachments), in writing, by 2:00 p.m. Eastern Time, 31 December 2026 to
Herbert Keen at herbert.e.keen.civ@health.mil and Mr. Lance Nowell at lance.l.nowell.civ@health.mil. Supporting evidence must be furnished in sufficient detail to demonstrate the firm’s ability to provide the stated capability. Information and materials submitted in response to theis request WILL NOT be returned. DO NOT SUBMIT CLASSIFIED MATERIAL.
Responses will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses to this notice is solely within the discretion of the
Government. If no responses are received, the DHACA will proceed with the sole source contract issued to Mitochon Pharmaceuticals, Inc.
mailto:herbert.e.keen.civ@health.mil mailto:lance.l.nowell.civ@health.mil
File details come from the government source that posted it. Updated .